Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patients
M. Venturini, F. Cognetti(Sapienza University of Rome), L. Frevola, R. Rosso(Research Institute for Geo-Hydrological Protection), M. Bergaglio(Alleanza Contro il Cancro), C. Sguotti, Sara Donati(Ospedale Versilia), Rita Lionetto, Paola Papaldo(Cancer Institute (WIA)), Andrea Michelotti(University of Pisa), Lucia Del Mastro(Ospedale Policlinico San Martino), Gianluigi Lunardi(Ospedale Sacro Cuore Don Calabria)
Cited by 24
Related Papers
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
|The Lancet|2007|912
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype
|Cancer Treatment Reviews|2018|282
Activity of gemcitabine in patients with non-small cell lung cancer: A multicentre, extended phase II study
|European Journal of Cancer|1996|242